Injectable Drug Delivery Market Share, Industry Report 2032

Injectable Drug Delivery Market - By Devices (Autoinjectors, Pen Injectors, Wearable & Needle-free Injectors), Formulation, Formulation Packing, Application, Site of Administration, Usage Pattern, Usability, End-use – Global Forecast (2024 – 2032)

Report Content

Chapter 1&nbsp; &nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Escalation in demand for self-injection devices

3.2.1.2&nbsp;&nbsp;&nbsp; Increase in the number of chronic diseases

3.2.1.3&nbsp;&nbsp;&nbsp; Innovative technological progress

3.2.1.4&nbsp;&nbsp;&nbsp; Development of the biologics market

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Needlestick injuries and infections

3.2.2.2&nbsp;&nbsp;&nbsp; Preference over other drug delivery systems

3.2.2.3&nbsp;&nbsp;&nbsp; Sterility of injectables

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Reimbursement scenario

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Technological landscape

3.6.1&nbsp;&nbsp;&nbsp; Core technologies

3.6.2&nbsp;&nbsp;&nbsp; Adjacent technologies

3.7&nbsp;&nbsp;&nbsp; Pricing analysis, 2023

3.7.1&nbsp;&nbsp;&nbsp; By region

3.7.2&nbsp;&nbsp;&nbsp; By key player

3.8&nbsp;&nbsp;&nbsp; Future market trends

3.9&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.10&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp; Market Estimates and Forecast, By Devices, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Conventional injection devices

5.2.1&nbsp;&nbsp;&nbsp; Fillable syringes

5.2.2&nbsp;&nbsp;&nbsp; Prefilled syringes

5.3&nbsp;&nbsp;&nbsp; Self-injection devices

5.4&nbsp;&nbsp;&nbsp; Needle-free injectors

5.4.1&nbsp;&nbsp;&nbsp; Jet-based needle-free injectors

5.4.2&nbsp;&nbsp;&nbsp; Spring-based needle-free injectors

5.4.3&nbsp;&nbsp;&nbsp; Laser-powered needle-free injectors

5.4.4&nbsp;&nbsp;&nbsp; Vibration-based needle-free injectors

5.5&nbsp;&nbsp;&nbsp; Autoinjectors

5.5.1&nbsp;&nbsp;&nbsp; Automated autoinjectors

5.5.2&nbsp;&nbsp;&nbsp; Manual autoinjectors

5.6&nbsp;&nbsp;&nbsp; Pen injectors

5.6.1&nbsp;&nbsp;&nbsp; Single-chambered pen injectors

5.6.2&nbsp;&nbsp;&nbsp; Dual-chambered pen injectors

5.7&nbsp;&nbsp;&nbsp; Wearable injectors

5.8&nbsp;&nbsp;&nbsp; Other devices

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Formulation, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Conventional drug delivery formulations

6.2.1&nbsp;&nbsp;&nbsp; Solutions

6.2.2&nbsp;&nbsp;&nbsp; Reconstituted/lyophilized formulations

6.2.3&nbsp;&nbsp;&nbsp; Suspensions

6.2.4&nbsp;&nbsp;&nbsp; Emulsions

6.3&nbsp;&nbsp;&nbsp; Novel drug delivery formulations

6.3.1&nbsp;&nbsp;&nbsp; Colloidal dispersions

6.3.2&nbsp;&nbsp;&nbsp; Niosomes

6.3.3&nbsp;&nbsp;&nbsp; Liposomes

6.3.4&nbsp;&nbsp;&nbsp; Polymeric/mixed micelles

6.3.5&nbsp;&nbsp;&nbsp; Nanoparticles

6.3.6&nbsp;&nbsp;&nbsp; Solid-lipid nanoparticles

6.3.7&nbsp;&nbsp;&nbsp; Nanosuspensions

6.3.8&nbsp;&nbsp;&nbsp; Nanoemulsions

6.4&nbsp;&nbsp;&nbsp; Microparticles

6.4.1&nbsp;&nbsp;&nbsp; Microspheres

6.4.2&nbsp;&nbsp;&nbsp; Microcapsules

6.5&nbsp;&nbsp;&nbsp; Long-acting injection formulations

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Formulation Packing, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Ampoules

7.3&nbsp;&nbsp;&nbsp; Vials

7.4&nbsp;&nbsp;&nbsp; Cartridges

7.5&nbsp;&nbsp;&nbsp; Bottles

Chapter&nbsp; 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Application, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Autoimmune diseases

8.2.1&nbsp;&nbsp;&nbsp; Rheumatoid arthritis

8.2.2&nbsp;&nbsp;&nbsp; Multiple sclerosis

8.2.3&nbsp;&nbsp;&nbsp; Crohn&#39;s disease

8.2.4&nbsp;&nbsp;&nbsp; Psoriasis

8.2.5&nbsp;&nbsp;&nbsp; Other autoimmune diseases

8.3&nbsp;&nbsp;&nbsp; Hormonal disorders

8.3.1&nbsp;&nbsp;&nbsp; Diabetes

8.3.2&nbsp;&nbsp;&nbsp; Anemia

8.3.3&nbsp;&nbsp;&nbsp; Reproductive health disease

8.3.4&nbsp;&nbsp;&nbsp; Antithrombotic/thrombolytic therapy

8.3.5&nbsp;&nbsp;&nbsp; Osteoporosis

8.3.6&nbsp;&nbsp;&nbsp; Growth hormone deficiency

8.4&nbsp;&nbsp;&nbsp; Orphan diseases

8.5&nbsp;&nbsp;&nbsp; Cancer

8.6&nbsp;&nbsp;&nbsp; Infectious diseases

8.7&nbsp;&nbsp;&nbsp; Other applications

Chapter 9&nbsp;&nbsp;Market Estimates and Forecast, By Site of Administration, 2021 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; Skin

9.3&nbsp;&nbsp;&nbsp; Circulatory/musculoskeletal system

9.4&nbsp;&nbsp;&nbsp; Organs

9.5&nbsp;&nbsp;&nbsp; Central nervous system

Chapter 10&nbsp; &nbsp;Market Estimates and Forecast, By Usage Pattern, 2021 &ndash; 2032 ($ Mn)

10.1&nbsp;&nbsp;&nbsp; Key trends

10.2&nbsp;&nbsp;&nbsp; Curative care

10.3&nbsp;&nbsp;&nbsp; Immunization

10.4&nbsp;&nbsp;&nbsp; Other usage patterns

Chapter 11&nbsp; Market Estimates and Forecast, By Usability, 2021 &ndash; 2032 ($ Mn)

11.1&nbsp;&nbsp;&nbsp; Key trends

11.2&nbsp;&nbsp;&nbsp; Disposable

11.3&nbsp;&nbsp;&nbsp; Reusable

Chapter 12&nbsp; &nbsp;Market Estimates and Forecast, By End-use, 2021 &ndash; 2032 ($ Mn)

12.1&nbsp;&nbsp;&nbsp; Key trends

12.2&nbsp;&nbsp;&nbsp; Hospitals and clinics

12.3&nbsp;&nbsp;&nbsp; Ambulatory surgical centers

12.4&nbsp;&nbsp;&nbsp; Home care settings

12.5&nbsp;&nbsp;&nbsp; Other end-users

Chapter 13&nbsp; &nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

13.1&nbsp;&nbsp;&nbsp; Key trends

13.2&nbsp;&nbsp;&nbsp; North America

13.2.1&nbsp;&nbsp;&nbsp;U.S.

13.2.2&nbsp;&nbsp;&nbsp;Canada

13.3&nbsp;&nbsp;&nbsp; Europe

13.3.1&nbsp;&nbsp;&nbsp;Germany

13.3.2&nbsp;&nbsp;&nbsp;UK

13.3.3&nbsp;&nbsp;&nbsp;France

13.3.4&nbsp;&nbsp;&nbsp;Spain

13.3.5&nbsp;&nbsp;&nbsp;Italy

13.3.6&nbsp;&nbsp;&nbsp;Netherlands

13.3.7&nbsp;&nbsp;&nbsp;Rest of Europe

13.4&nbsp;&nbsp;&nbsp; Asia Pacific

13.4.1&nbsp;&nbsp;&nbsp;China

13.4.2&nbsp;&nbsp;&nbsp;Japan

13.4.3&nbsp;&nbsp;&nbsp;India

13.4.4&nbsp;&nbsp;&nbsp;Australia

13.4.5&nbsp;&nbsp;&nbsp;South Korea

13.4.6&nbsp;&nbsp;&nbsp;Rest of Asia Pacific

13.5&nbsp;&nbsp;&nbsp; Latin America

13.5.1&nbsp;&nbsp;&nbsp;Brazil

13.5.2&nbsp;&nbsp;&nbsp;Mexico

13.5.3&nbsp;&nbsp;&nbsp;Argentina

13.5.4&nbsp;&nbsp;&nbsp;Rest of Latin America

13.6&nbsp;&nbsp;&nbsp; Middle East and Africa

13.6.1&nbsp;&nbsp;&nbsp;South Africa

13.6.2&nbsp;&nbsp;&nbsp;Saudi Arabia

13.6.3&nbsp;&nbsp;&nbsp;UAE

13.6.4&nbsp;&nbsp;&nbsp;Rest of Middle East and Africa

Chapter 14 Company Profiles

14.1&nbsp;&nbsp;&nbsp; A. Menarini Diagnostics s.r.l

14.2&nbsp;&nbsp;&nbsp; Abbott Laboratories

14.3&nbsp;&nbsp;&nbsp; ARKRAY, Inc.

14.4&nbsp;&nbsp;&nbsp; Becton, Dickinson and Company

14.5&nbsp;&nbsp;&nbsp; Bio-Rad Laboratories, Inc.

14.6&nbsp;&nbsp;&nbsp; Ceragem Medisys Inc.

14.7&nbsp;&nbsp;&nbsp; Danaher Corporation

14.8&nbsp;&nbsp;&nbsp; EKF Diagnostics

14.9&nbsp;&nbsp;&nbsp; Eli Lilly and Company

14.10&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd.

14.11&nbsp;&nbsp;&nbsp; Pfizer Inc.

14.12&nbsp;&nbsp;&nbsp; PTS Diagnostics

14.13&nbsp;&nbsp;&nbsp; SAKAE HOLDINGS LTD.

14.14&nbsp;&nbsp;&nbsp; Sanofi

14.15&nbsp;&nbsp;&nbsp; SEKISUI CHEMICAL CO., LTD.

14.16&nbsp;&nbsp;&nbsp; Siemens Healthineers AG

14.17&nbsp;&nbsp;&nbsp; Trinity Biotech plc 
&nbsp;

Injectable Drug Delivery Market

Get a free sample of this report